BIOTRICITY Business Summary

Biotricity Inc. (BTCY) operates as a Technology-as-a-Service (TaaS) provider specializing in remote cardiac monitoring and chronic care management. The company generates revenue through a high-margin recurring model, where "Technology Fees" for monitoring services account for approximately 91% of total revenue, supplemented by one-time medical device sales. Its primary business segments include the clinical-grade Bioflux mobile cardiac telemetry (MCT) system, the Biocore Pro long-term Holter monitor, and the Bioheart consumer-facing wearable. Biotricity differentiates itself through a provider-centric "insourcing" model that allows physicians to retain diagnostic control and billing rights, utilizing a proprietary 3-channel AI cloud platform that offers higher diagnostic yield than traditional 1- or 2-channel systems. Direct competitors include iRhythm Technologies (Zio), Boston Scientific (Preventice), Baxter (Bardy Diagnostics), and Philips (BioTelemetry); Biotricity occupies a high-growth niche by bridging the gap between episodic diagnostic care and continuous, proactive chronic disease management. The leadership team is led by Founder, CEO, and Chairman Dr. Waqaas Al-Siddiq, a serial entrepreneur with a PhD in Computer Engineering and extensive experience in wireless communication and data security. He is supported by CFO John Ayanoglou, a 30-year finance veteran who previously served as CFO for four public companies and was instrumental in raising over $130 million in regulatory capital at Equitable Bank. Chief Development Officer Amir Ali brings over 20 years of expertise in network computing and cloud-based applications, formerly serving as CEO of AT Labs. The executive suite also includes Dr. Fareeha Siddiqui as Senior VP of Healthcare Solutions, focusing on clinical integration and public-private partnerships. Notable institutional backing includes a significant $12 million capital infusion from SWK Funding LLC, which has accelerated the company's trajectory toward full net income profitability in 2026.